Home > Journals > Minerva Gastroenterology > Past Issues > Minerva Gastroenterology 2021 September;67(3) > Minerva Gastroenterology 2021 September;67(3):244-53

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  IMPACT OF DIRECT ANTIVIRAL AGENTS (DAAS) ON EXTRAHEPATIC DISEASES IN PATIENTS WITH CHRONIC HEPATITIS C 

Minerva Gastroenterology 2021 September;67(3):244-53

DOI: 10.23736/S2724-5985.21.02849-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Impact of antiviral therapy with direct acting antiviral agents (DAAs) on kidney disease in patients with chronic hepatitis C

Fabrizio FABRIZI 1 , Roberta CERUTTI 1, Carlo M. ALFIERI 1, 2, Ezequiel RIDRUEJO 3, 4

1 Division of Nephrology, Dialysis, and Transplantation, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 2 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 3 Section of Hepatology, Department of Medicine, Centro de Educaciòn Medica e Investigaciones Clinicas Norberto Quirno (CEMIC), Buenos Aires, Argentina; 4 Latin American Liver Research, Educational and Awareness Network (LALREAN), Buenos Aires, Argentina



Hepatitis C virus and chronic kidney disease are major public health issues all over the world and controversy persists regarding the role of Hepatitis C as a risk factor for the development of chronic kidney disease in the adult general population. Numerous studies found a relationship between positive anti-HCV antibody serologic prevalence and increased frequency of incidence, prevalence and accelerated progression of chronic kidney disease (CKD) over time. However, this has not been universally accepted. One method to analyze the relationship between anti-HCV status and CKD is to evaluate the impact of anti-HCV antiviral therapy on the risk of CKD in the general population. The availability of safe and effective drugs (direct-acting antiviral agents) for HCV eradication supports this approach. Novel data support the notion that sustained viral response with anti-HCV regimens leads to improvement of hepatic and extrahepatic outcomes. A systematic review with meta-analysis of clinical observational studies was recently performed on this point. Fifteen studies were retrieved (N.=356, 285 patients); a relationship between sustained viral response and lower rate of kidney disease was noted- the summary estimate for adjusted risk of kidney disease was 2.5 (95% CI: 1.41; 4.41) (P=0.0016). An association between anti-HCV therapy and reduced risk of kidney disease after comparison of treated vs. untreated cohorts was observed, the summary estimate for adjusted HR was 0.44 (95% CI: 0.25; 0.63) (P=0.0001). Several biologic mechanisms have been cited to explain the detrimental role of HCV on kidney disease in the general population, and a direct and indirect activity of HCV on atherogenesis at kidney level has been mentioned. Clinical and experimental studies are under way.


KEY WORDS: Antiviral agents; Hepatitis C; Kidney disease

top of page